COVISTA INC (CVSA)
Consumer Discretionary · postsecondary education and professional training · NYSE
Covista Inc. is a leading US healthcare education provider offering degree and certificate programs across nursing, medicine, and veterinary fields to address critical workforce shortages.
What COVISTA INC does
Covista Inc. is a major US healthcare educator that operates through five accredited institutions: Chamberlain University, Walden University, and three medical and veterinary schools (AUC, RUSM, and RUSVM). The company provides degree and certificate programs, both onsite and online, across disciplines including nursing, medicine, veterinary medicine, social sciences, and various professional fields. Its strategy is focused on expanding access to healthcare education to help address the U.S. healthcare workforce shortage.
Themes: healthcare education, nursing workforce training, online higher education, medical school training, veterinary medicine education, professional certification programs
Fundamentals
- Price$132.35 as of 2026-08-21 close
- Market cap$4.5B as of 2026-08-21
- 1-year return-0.4% 2025-08-21 close $132.89 → 2026-08-21 close $132.35
- P/E19.22 as of 2026-08-24
- Net margin+12.3% as of 2026-08-24
- Gross margin+57.3% as of 2026-08-24
- ROE+16.6% as of 2026-08-24
- Debt / equity0.37 as of 2026-08-24
- Revenue growth (YoY)+9.7% as of 2026-08-24
- Revenue CAGR (3y)+10.4% SEC XBRL
- Beta0.65 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How CVSA compares in its sector
- price-to-earnings ratiomiddle range 266 covered Consumer Discretionary peers, as of 2026-08-24
- net profit margintop 25% 334 covered Consumer Discretionary peers, as of 2026-08-24
- operating margintop 25% 334 covered Consumer Discretionary peers, as of 2026-08-24
- gross margintop 25% 331 covered Consumer Discretionary peers, as of 2026-08-24
- return on equitymiddle range 334 covered Consumer Discretionary peers, as of 2026-08-24
- 3-year revenue CAGRtop 25% 325 covered Consumer Discretionary peers
- free cash flow (absolute dollars, latest fiscal year)middle range 311 covered Consumer Discretionary peers, as of FY2026
Position among covered Consumer Discretionary companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
CVSA is not currently in any published Top 10 list. Its scores are below.
Long-term score
53.9 #361 of 987 scored · #21 of 115 in Consumer Discretionary
Financial health 70th (debt to equity 0.4) and growth 68th (3-year revenue CAGR 10.4%, revenue growth year over year 9.7%); weakest is capital return (2nd, consecutive years of dividend increases 0 years).
Short-term score
60.6 #181 of 1,704 scored · #18 of 186 in Consumer Discretionary
Volume and participation 82nd: trading volume is about normal versus its 30-day average; setup 75th: no fresh 20-day breakout up or down; weakest is catalysts 24th: analysts have cut their average price target by 2.3% since the prior reading.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
Dividend coverage
Not assessed — last reported dividend predates the accounts. The most recent fiscal year in which CVSA reported a dividend payment is FY2017, while its reported financial statements run through FY2026. Coverage is therefore not assessed for the latest year — an FY2017 ratio would not describe CVSA today.
Coverage is derived from reported SEC EDGAR XBRL figures, comparing dividends paid against net income and free cash flow for the SAME fiscal year. It is not shown here because the latest fiscal year with a reported dividend payment (FY2017) is older than the latest year of reported financial statements (FY2026), so any ratio would describe an out-of-date year. Informational only — not financial advice.
How COVISTA INC looks technically
COVISTA INC (CVSA) is trading 17.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 60 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 11 trading days ago. It is 15.3% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 17.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +17.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $126.04 | $126.04 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $112.59 | $112.59 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 60 trading days ago — a "golden cross", a bullish long-term signal | 60 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 17.5% above | +17.6% |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend) | 21.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30) | 54.4 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($122.07 to $141.91) — its "stochastic" reading is 52 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 51.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 18 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $156.26 | $156.26 |
|---|---|---|
| From the 52-week high | it is 15.3% below its 52-week high (its highest price of the past year) | -15.3% |
| Above the 52-week low | it is 52.2% above its 52-week low (its lowest price of the past year) | +52.2% |
| Below the 52-week high | it is 15.3% below its highest point of the past year | 15.3% |
| Since a 20-day breakout | it made a new 20-day high about 11 trading days ago | 11 sessions |
| Since a 55-day breakout | it made a new 55-day high about 11 trading days ago | 11 sessions |
| All-time high | its highest closing price on record is $156.26 (set on 2025-10-24) | $156.26 |
| Given back of the 52-week move | over the past year its closes ranged ($89.36 to $154.45), and it has recovered well over two thirds of its fall from last year’s high — 66% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $129.59 to $131.67. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 66.0% |
| From the all-time high | it is 15.3% below its all-time high | -15.3% |
| Nearest price level | it is trading 1.3% above a support level at $130.68 — a price it turned at five times since 2025-06-27, most recently on 2026-05-19. Since 2024-08-21 it has 15 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.3% |
| All-time low | its lowest closing price on record is $1.09 (set on 1991-06-26) | $1.09 |
| Above the all-time low | it is 12000.6% above its all-time low | +12,001% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 33rd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $6.01 between its high and its low — about 4.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $6.01 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $120.85 and $137.79 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $120.85 – $129.32 – $137.79 |
| Typical daily range (% of price) | its price moves about 4.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.5% |
| Stretch from the 200-day average | it is trading 3.3 daily ranges above its 200-day average price (17.6% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.16× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 2.3% since the prior reading | -2.4% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 5 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 5 sessions ago |
|---|---|---|
| Since a hammer | 5 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 5 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.2% |
|---|---|---|
| Gap filled | a 2.4% gap up opened on 2026-08-07 has been "filled" 10 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 10 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 11.4 percentage points (the stock gained 13.8% while the market gained 2.3%) | +11.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 3.6 percentage points (the stock gained 6.7% while the market gained 3.1%) | +3.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 25.9 percentage points (the stock gained 37.0% while the market gained 11.1%) | +25.9% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 20.9 percentage points (the stock lost 0.4% while the market gained 20.5%) | -20.9% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 5.3% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-15 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 1.4% of the share price, which is taken to mean a barrier that gives way easily. | +5.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 15% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $115.46 — a volume-weighted average of daily closes over 159 sessions, not a true tick-by-tick VWAP. | +14.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% above the average price paid since it last reported on 2026-08-06 (its 10-K), so the typical buyer over that stretch is showing a gain. That average is $131.00 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +1.0% |
Price levels it has turned at before
CVSA last closed at $132.35 on 2026-08-21. Since 2024-08-21 it has turned at 15 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $130.68 | Support | 1.3% below the last close | turned there five times · 2025-06-27 to 2026-05-19 |
| $134.50 | Resistance | 1.6% above the last close | turned there four times · 2025-06-03 to 2026-07-29 |
| $125.28 | Support | 5.3% below the last close | turned there twice · 2025-05-23 to 2026-01-29 |
| $141.22 | Resistance | 6.7% above the last close | turned there three times · 2025-05-12 to 2026-08-07 |
| $118.68 | Support | 10.3% below the last close | turned there three times · 2025-07-02 to 2026-04-20 |
| $155.82 | Resistance | 17.7% above the last close | turned there twice · 2025-09-30 to 2025-10-24 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Analyst price target recently CUT · beating the market · Near the golden pocket (has given back about two thirds of its 52-week move) · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.25 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$159.50 range $140.00 – $175.00; median $161.50
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CVSA
- Consensus EPS estimate$1.84 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant regulatory scrutiny and compliance requirements common to the postsecondary education sector.","Dependence on student enrollment levels and the ability to maintain accreditation across its institutions."]
What changed in the latest 10-Q
AI-assisted comparison of CVSA's 10-Q filed 2026-05-07 against the prior one filed 2026-01-28.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to '2025 Form 10-K' for fiscal year ended June 30, 2025 (added in newer filing)
- Third Quarter Highlights section with Q3 FY2026 financial metrics (revenue $487.0M, net income $41.6M, diluted EPS $1.20, adjusted net income $69.0M, adjusted EPS $1.98)
- Reference to Walden academic week shift from Q3 to Q2 resulting in $18.0M revenue recognition in Q2
- Chamberlain enrollment changes for January 2026 (down 0.7%) and March 2026 (up 0.5%)
- Walden enrollment increase of 12.3% as of March 31, 2026
- Medical and veterinary schools enrollment increase of 4.1% for January 2026 semester
- Information about Term Loan B Amendment on March 2, 2026 ($510.0M new term loans, maturity March 2, 2033, repayment of $103.3M prior Term Loan B and $405.0M Senior Secured Notes due 2028)
- Share repurchase details: 637,538 shares at $103.04 average cost in Q3 FY2026
- Removed:
- Reference to annual Form 10-K and related MD&A from prior reporting (older filing referenced consolidated statements in conjunction with Form 10-K)
- Second Quarter Highlights section with Q2 FY2026 metrics (revenue $503.4M, net income $76.4M, diluted EPS $2.11, adjusted net income $87.9M, adjusted EPS $2.43)
- Chamberlain enrollment change for November 2025 (down 1.0%)
- Walden enrollment as of December 31, 2025 (13.0% increase)
- Share repurchase details from Q2: 1,727,565 shares at $95.45 average cost
- One Big Beautiful Bill Act section discussing OBBBA provisions, Grad PLUS phaseout, federal loan caps, and part-time enrollment borrowing limits
- Reworded:
- Company name changed from 'Adtalem' to 'Covista' throughout (including website www.adtalem.com to www.covista.com)
- Fiscal period changed from 'second quarter' ended December 31, 2025 to 'third quarter' ended March 31, 2026
- MD&A reference language: older version states 'should be read in conjunction with the Cautionary Disclosure...' while newer version states 'should be read with and is qualified in its entirety by the Consolidated Financial Statements and... It should also be read in conjunction with our consolidated financial statements and the related Management's Discussion and Analysis'
- Available Information section: reference to 'investors should monitor' (older) changed to 'you should monitor' (newer); 'Investors and others can receive' (older) changed to 'You can receive' (newer)
- Segment Information note reference: 'Adtalem's reportable segments' changed to 'Covista's reportable segments'
- Notes:
- The older filing appears to have metadata labeling it with 'ATGE' ticker in filename (atge-20251231x10q.htm) despite company name being Adtalem; newer filing uses 'CVSA' and company name Covista, suggesting a potential company name/ticker change between filings
- The newer filing text appears truncated at the end of the share repurchase sentence ('The timing and amount of any f'), preventing full assessment of that section
- Older filing OBBBA discussion section is truncated ('The annual limit for students in non-professional graduate programs remains at the current level of $20,500; eventually phasing out...and part-time enrollment borrowing limits'), so complete removal of that section cannot be fully verified
Risk Factors
- Added:
- Newer filing (2026-05-07) shows company name as 'Covista Inc.' instead of 'Adtalem Global Education Inc.'
- Newer filing includes 'Current portion of long-term debt' line item ($3,825 thousand) in current liabilities, not present in older filing
- Newer filing reports nine-month period ended March 31, 2026 in consolidated statements of income, compared to six-month period ended December 31, 2025 in older filing
- Newer filing cash flow statement covers nine-month period ended March 31, 2026 with comparative nine-month period ended March 31, 2025, compared to six-month period ended December 31, 2025 with comparative six-month period ended December 31, 2024 in older filing
- Removed:
- Older filing (2026-01-28) included 'Accrued excise tax on share repurchases' line item ($1,089 thousand) in non-cash activities, not present in newer filing
- Older filing included comparison for six-month periods; newer filing removed six-month period comparison and uses nine-month periods instead
- Reworded:
- Balance sheet date changed from 'December 31, 2025' in older filing to 'March 31, 2026' in newer filing
- Income statement periods changed from 'Three Months Ended December 31' and 'Six Months Ended December 31' in older filing to 'Three Months Ended March 31' and 'Nine Months Ended March 31' in newer filing
- Cash flow statement periods changed from 'Six Months Ended December 31' in older filing to 'Nine Months Ended March 31' in newer filing
- Notes:
- The two filings appear to represent different reporting periods and companies (name change from Adtalem Global Education Inc. to Covista Inc.), which affects comparability of the underlying financial data
- The change from six-month to nine-month reporting periods in the newer filing makes year-over-year comparisons of income statement and cash flow metrics less directly comparable
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 7 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 7 sells ($3M) — 3 selling insiders
- Last 180 days3 buys ($4M) · 11 sells ($8M) — 1 buying, 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-13. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CVSA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding CVSA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 9,414,373
- Reported value $1,085,006,444
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 4 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
CVSA had 1,651,144 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
CVSA had 4.85% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.73 days to cover at the same settlement.
- Reported short interest (shares) 1,651,144
- Short interest (% of shares outstanding) 4.85%
- Prior settlement (shares) 1,682,699
- Reported change -1.88%
- Days to cover (reported) 4.73
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Grand Canyon Education (LOPE)
- Strayer Education (STRA)
- Perdoceo Education (PRDO)
- Career Education Corporation
- Universal Technical Institute (UTI)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CVSA vs…
Frequently asked questions
What does COVISTA INC (CVSA) do?
Covista Inc. is a major US healthcare educator that operates through five accredited institutions: Chamberlain University, Walden University, and three medical and veterinary schools (AUC, RUSM, and RUSVM). The company provides degree and certificate programs, both onsite and online, across disciplines including nursing, medicine, veterinary medicine, social sciences, and various professional fields. Its strategy is focused on expanding access to healthcare education to help address the U.S.
What sector is COVISTA INC (CVSA) in?
COVISTA INC (CVSA) is classified in the Consumer Discretionary sector. Its industry is postsecondary education and professional training. It trades on NYSE.
Who are COVISTA INC's (CVSA) competitors?
Notable peers of COVISTA INC (CVSA) include Grand Canyon Education, Strayer Education, Perdoceo Education, Career Education Corporation and Universal Technical Institute. This peer set is informational only — not financial advice.
Is COVISTA INC (CVSA) overbought or oversold right now?
COVISTA INC (CVSA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 54, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CVSA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.